• AstraZeneca’s Trixeo (Breztri) Aerosphere budesonide / glycopyrrolate / formoterol MDI approved by the EU for the treatment of asthma

  AstraZeneca announced that the European Commission has approved the company’s Trixeo (Breztri) Aerosphere budesonide / glycopyrrolate / formoterol MDI for the treatment of asthma in patients aged 12 and older whose asthma is not adequately… [Read more . . .]

• CF Pharmtech initiates Phase 1 trial of ICF004 antifibrotic DPI

  Chinese OINDP developer CF Pharmtech has announced the initiation of its Phase 1 trial of its ICF004 dry powder inhaler, which the company is developing for the treatment of fibrotic lung diseases. The study record… [Read more . . .]

• Polyrizon initiates trial of Nasarix (PL-14) intranasal allergen blocker for seasonal allergic rhinitis

  Polyrizon has announced the initiation of its first clinical trial, a study of its Nasarix (PL-14) hydrogel nasal spray in patients with seasonal allergic rhinitis. In September 2025, the company said that it had submitted… [Read more . . .]

• Bespak and Upperton team up to offer nasal drug development and manufacturing services

  OINDP specialist CDMOs Bespak and Upperton have announced a new strategic collaboration that will offer services based on Upperton’s UpperNose nasal development platform and manufacturing capability in conjunction with Bespak nasal delivery devices. The announcement… [Read more . . .]

• FDA accepts Insmed’s sNDA to expand the use of Arikayce amikacin liposome inhalation suspension for MAC lung disease

  Insmed announced that the FDA has accepted the company’s sNDA to expand the use of Arikayce amikacin liposome inhalation suspension for the treatment of Mycobacterium avium complex (MAC) lung disease. Arikayce is delivered by PARI‘s Lamira nebulizer. According to… [Read more . . .]

• SpliSense initiates Phase 2b trial of SPL84 inhaled antisense oligonucleotide for the treatment of cystic fibrosis

• FDA clears IND for Phase 1b trial of SMSbiotech’s inhaled stem cell therapy in patients with COPD

• Ritedose Corporation names Carolyn Berg as VP of Strategic Growth

• FDA approves Aurobindo’s generic beclomethasone MDI

• Zeteo Biomedical announces the launch of its new AriesMR active DPI

More news . . .